Select Page

Press

  • Annie De Groot Presents to NIH/NIAID on Next Generation Epitope-Driven Vaccines

    Posted on May 4, 2009 by epivax3
    In early May, Dr. Annie De Groot will be presenting to the NIH/NIAID regarding next generation epitope-driven vaccines: "More Effector Epitopes, Less Heterologous Epitopes, and no T-regitopes?" The presentation will be hosted by David Sacks, PhD, Chief of Intracellular Parasite Biology Section for the National Institute on Allergy and Infectious Diseases.   While whole killed, whole protein, ...
    Read more
  • Dr. Annie De Groot chosen for PBN Overall Career Achievement Award

    Posted on April 28, 2009 by epivax3
    The Providence Business News has chosen Dr. Annie De Groot as this year's receipient of the Overall Career Achievement Award. From the nomination: Dr. De Groot has a vision for Rhode Island; she sees our state as being the leader in biotechnology, an engine in the new knowledge economy, and a model for economic redevelopment to the ...
    Read more
  • Daughter, Father Reunite at URI Lab

    Posted on February 24, 2009 by epivax3
    http://www.projo.com/business/content/BZ_FATHER_DAUGHTER_02-24-09_H5DCTR0_v45.3093601.html PROVIDENCE – The equipment and building are new, but there is something familiar about Annie De Groot’s new digs: her father, who was among her first faculty appointments at the University of Rhode Island. When Annie De Groot, a Brown University professor and the chief executive officer of EpiVax, was given the job of directing ...
    Read more
  • New lab will research vaccines

    Posted on February 24, 2009 by epivax3
    http://www.projo.com/business/content/BZ_INFORMATICS_02-24-09_H5DCOE1_v111.308ebf3.html PROVIDENCE –– The University of Rhode Island has hired the founder of one of the state’s best-known biotechnology firms to lead researchers in thedevelopment of vaccines against malaria, AIDS and tuberculosis. Annie S. De Groot, 53, is not leaving EpiVax Inc., the Providence-based company she helped create in 1998, building on software technology she developed ...
    Read more
  • URI taps De Groot to head new vaccine research center

    Posted on February 24, 2009 by epivax3
    http://www.masshightech.com/stories/2009/02/09/daily43-URI-taps-De-Groot-to-head-new-vaccine-research-center.html The University of Rhode Island’s (URI) biotechnology center in Providence is creating an institute to research the prevention and cure of so-called neglected animal and human diseases, which will be led by Annie De Groot, the CEO of biotech EpiVax Inc. The purpose of the new program, called the Institute for Immunology and Informatics, is to ...
    Read more
  • EpiVax Receives NIH Grant for $390,000 to Optimize HIV Vaccine Delivery

    Posted on December 1, 2008 by epivax3
    EpiVax Receives NIH Grant for $390,000 to Optimize HIV Vaccine Delivery December 1, 2008 (Providence, RI)–EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received a grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to optimize delivery of ...
    Read more
  • EpiVax Profiled as "Tech Firm in RI to Watch"

    Posted on November 6, 2008 by Annie De Groot
    EpiVax was profiled in an article for Xconomy, which lists five "firms to watch" in Rhode Island who have utilized innovative strategies to grow their companies despite an period of economic downturn that has affected both the state and the country. Specifically, the article states that: "EpiVax uses an informatics system developed by founder and CEO Annie De ...
    Read more
  • EpiVax Profiled as “Tech Firm in RI to Watch”

    Posted on November 6, 2008 by epivax3
    EpiVax was profiled in an article for Xconomy, which lists five "firms to watch" in Rhode Island who have utilized innovative strategies to grow their companies despite an period of economic downturn that has affected both the state and the country. Specifically, the article states that: "EpiVax uses an informatics system developed by founder and CEO Annie De ...
    Read more
  • EpiVax Receives Tech Citizenship Award from Mass High Tech

    Posted on October 30, 2008 by epivax3
    EpiVax, Inc. has been named as a recipient of the Mass High Tech's 8th Annual Tech Citizenship Awards, which honors technology companies that give back more than one-half of 1 percent of annual reveue. Mass High Tech is the publisher of The Journal of New England Technology. This year's awardees will be honored at an event at the ...
    Read more
  • Publication on “Tregitopes” in Blood Journal of October 2008

    Posted on October 23, 2008 by epivax3
    October 8, 2008 (Providence, RI)–Dr. Annie De Groot, CEO of EpiVax, is the lead author on an article highlighting key findings about the activation of natural regulatory T cells by IgG Fc–derived peptide, also known as Epi-13 or “Tregitopes.” These findings were published in the October 8 issue of the prestigious Blood, the medical journal ...
    Read more
  • Dr. Annie De Groot, CEO, awarded YWCA 2008 Women of Achievement Award

    Posted on September 29, 2008 by epivax3
    http://www.sheshines.org/content/view/432/443/ She addresses healthcare concerns. Dr. Annie De Groot is CEO and founder of EpiVax, Inc.; co-chief editor and founder of Infectious Diseases in Corrections Report; scientific director and founder of GAIA Vaccine Foundation, and interim medical director and founding member of Clinica Esperanza/Hope Clinic. She designs new vaccines for diseases, offers healthcare in Providence and ...
    Read more
  • EpiVax awarded $35K Montel Williams Foundation grant for multiple sclerosis research

    Posted on September 29, 2008 by epivax3
    http://www.beloblog.com/ProJo_Blogs/bizblog/2008/09/providencebased-1.html The Montel Williams MS Foundation today announced a grant to Providence-based Epivax, Inc., the first biotech-related company to be awarded a grant from the foundation. Epivax is a privately held company run by Anne Searls DeGroot that is dedicated to the development and implementation of computational immunology tools to benefit the biotechnology industry. The size of ...
    Read more
  • EpiVax Recieves $600,000 NIH Grant to Further Research in Type 1 Diabetes

    Posted on September 29, 2008 by epivax3
    EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH), to develop “Epi-13”, a novel therapeutic for the prevention and treatment of Type 1 diabetes, a ...
    Read more
  • EpiVax Presents Tolerance-inducing “Tregitopes” at Keystone Conference

    Posted on January 25, 2008 by epivax3
    EpiVax Presents Tolerance-inducing "Tregitopes" at Keystone Conference February 7, 2008 (Providence, RI)—- EpiVax, Inc, a leader in the field of computational immunology, presented data at the Keystone Symposium on Tolerance and Transplantation (January 29-Feb 3, 2008), in Keystone Colorado confirming the activity of natural “Tregitopes” to induce tolerance to a wide range of antigens in vitro ...
    Read more
  • EpiVax Presents Tolerance-inducing “Tregitopes” at Keystone Conference

    Posted on January 25, 2008 by Annie De Groot
    EpiVax Presents Tolerance-inducing “Tregitopes” at Keystone Conference February 7, 2008 (Providence, RI)—- EpiVax, Inc, a leader in the field of computational immunology, presented data at the Keystone Symposium on Tolerance and Transplantation (January 29-Feb 3, 2008), in Keystone Colorado confirming the activity of natural “Tregitopes” to induce tolerance to a wide range of antigens in vitro ...
    Read more

Join our newsletter

We strive to provide our clients, collaborators and everyday immunology enthusiasts with valuable content.  Written by our CEO/CSO Dr. Anne Dr Groot, you can expect up to date vaccine development efforts, upcoming events and so much more from our offices here in Providence, RI.

Click Here